{
    "info": {
        "nct_id": "NCT05479812",
        "official_title": "A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors",
        "inclusion_criteria": "Each patient must meet all the following criteria to participate in the study:\n\n1. Has histological or cytological documentation of a solid tumor indication for which a CPI (e.g. anti-PD-(L)1 is indicated for all parts of the clinical study;\n2. Monotherapy Dose Escalation:\n\n   Patients with relapsed/refractory locally advanced or metastatic solid tumors for which immunotherapy is approved, who have progressed on or are intolerant to standard therapy, including CPIs, or for whom no standard therapy with proven benefit exists.\n\n   Combination Dose Escalation:\n\n   Patients with relapsed/refractory locally advanced or metastatic solid tumors for which immunotherapy is approved, who have progressed on or are intolerant to standard therapy or for whom no standard therapy with proven benefit exists.\n\n   Monotherapy Dose Expansion:\n   * Arm A: Patients with relapsed advanced or metastatic RCC who have received no more than 4 prior lines of therapy in the advanced or metastatic setting\n   * Arm B: Patients with relapsed advanced or metastatic cutaneous malignant melanoma who have received no more than 2 prior lines of therapy for BRAF V600 wild type and no more than 3 prior lines of therapy for BRAF V600 mutant melanoma.\n   * Arm C: Patients with relapsed advanced or metastatic cSCC who have received no more than 1 prior line of therapy\n\n   Combination Dose Expansion:\n   1. Arm D: Patients with RCC who have received no more than 3 prior lines of therapy\n   2. Arm E: Patients with cutaneous melanoma who may be naïve to all prior therapy for advanced or metastatic disease. For BRAF wild type melanoma, patients should have received no more than 2 prior lines of therapy. For BRAF V600 mutant disease, patients should have received no more than 3 prior lines of therapy.\n   3. Arm F: Patients with PD-L1-positive NSCLC who have received no more than 3 prior lines;\n3. ≥18 years of age;\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;\n5. Has at least 1 measurable lesion per RECIST 1.1(lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions);\n6. Agrees to undergo a pre-treatment and on-treatment biopsy of a primary or metastatic solid tumor lesion;\n7. Has adequate organ and bone marrow function;\n8. Willingness of men and women of reproductive potential to observe highly effective birth control for the duration of treatment and for 4 months following the last dose of study drug;\n9. Additional criteria may apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Have a history of another active malignancy (a second cancer) within the previous 2 years except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, presents a low risk of recurrence. These exceptions include, but are not limited to, basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast;\n2. Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease;\n3. Have received prior IL-2-directed therapy;\n4. Have had an allogeneic tissue/solid organ transplant;\n5. Have known symptomatic brain metastases requiring steroids;\n6. Have significant cardiovascular disease;\n7. Have an active autoimmune disease that required systemic treatment in the past 2 years;\n8. Diagnosis of immunodeficiency, is on immunosuppressive therapy, or is receiving chronic systemic or enteric steroid therapy\n9. Major surgery (excluding placement of vascular access) within 2 weeks prior to the first dose of study drug;\n10. Investigational agent or anticancer therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug;\n11. Has received prior radiotherapy within 2 weeks of start of study treatment. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease;\n12. Any unresolved toxicities from prior therapy greater than NCI CTCAE version 5.0 Grade 1 at the time of starting study drug with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy;\n13. Received a live or live-attenuated vaccine within 30 days of the first dose of study drug; Note: Administration of killed vaccines or other formats are allowed.\n14. Active, uncontrolled systemic bacterial, viral, or fungal infection;\n15. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease;\n16. Active infection as determined by hepatitis B surface antigen and hepatitis B core antibody, or hepatitis B virus DNA by quantitative polymerase chain reaction (qPCR) testing;\n17. Active infection as determined by hepatitis C virus (HCV) antibody or HCV RNA by qPCR testing;\n18. Pregnant or lactating;\n19. History of hypersensitivity to any of the study drug components;\n20. Additional criteria may apply.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "7. Has adequate organ and bone marrow function;",
                "criterions": [
                    {
                        "exact_snippets": "Has adequate organ and bone marrow function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has adequate organ and bone marrow function",
                        "criterion": "bone marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Has adequate organ and bone marrow function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has adequate organ and bone marrow function",
                        "criterion": "bone marrow function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Monotherapy Dose Expansion:",
                "criterions": [
                    {
                        "exact_snippets": "Monotherapy Dose Expansion",
                        "criterion": "treatment phase",
                        "requirement": {
                            "requirement_type": "phase",
                            "expected_value": "monotherapy dose expansion"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Monotherapy Dose Expansion",
                        "criterion": "treatment phase",
                        "requirement": {
                            "requirement_type": "phase",
                            "expected_value": "monotherapy dose expansion"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. ≥18 years of age;",
                "criterions": [
                    {
                        "exact_snippets": "≥18 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "≥18 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Monotherapy Dose Escalation:",
                "criterions": [
                    {
                        "exact_snippets": "Monotherapy Dose Escalation",
                        "criterion": "treatment regimen",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "monotherapy"
                        }
                    },
                    {
                        "exact_snippets": "Monotherapy Dose Escalation",
                        "criterion": "treatment regimen",
                        "requirement": {
                            "requirement_type": "phase",
                            "expected_value": "dose escalation"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Monotherapy Dose Escalation",
                        "criterion": "treatment regimen",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "monotherapy"
                        }
                    },
                    {
                        "exact_snippets": "Monotherapy Dose Escalation",
                        "criterion": "treatment regimen",
                        "requirement": {
                            "requirement_type": "phase",
                            "expected_value": "dose escalation"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Arm F: Patients with PD-L1-positive NSCLC who have received no more than 3 prior lines;",
                "criterions": [
                    {
                        "exact_snippets": "PD-L1-positive NSCLC",
                        "criterion": "NSCLC PD-L1 status",
                        "requirement": {
                            "requirement_type": "PD-L1 status",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "no more than 3 prior lines",
                        "criterion": "number of prior lines of therapy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "PD-L1-positive NSCLC",
                        "criterion": "NSCLC PD-L1 status",
                        "requirement": {
                            "requirement_type": "PD-L1 status",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "no more than 3 prior lines",
                        "criterion": "number of prior lines of therapy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1",
                        "criterion": "ECOG Performance Status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Arm E: Patients with cutaneous melanoma who may be naïve to all prior therapy for advanced or metastatic disease. For BRAF wild type melanoma, patients should have received no more than 2 prior lines of therapy. For BRAF V600 mutant disease, patients should have received no more than 3 prior lines of therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Patients with cutaneous melanoma",
                        "criterion": "cutaneous melanoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "may be naïve to all prior therapy for advanced or metastatic disease",
                        "criterion": "prior therapy for advanced or metastatic disease",
                        "requirement": {
                            "requirement_type": "naivety",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "For BRAF wild type melanoma, patients should have received no more than 2 prior lines of therapy",
                        "criterion": "BRAF wild type melanoma",
                        "requirement": {
                            "requirement_type": "prior lines of therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "For BRAF V600 mutant disease, patients should have received no more than 3 prior lines of therapy",
                        "criterion": "BRAF V600 mutant melanoma",
                        "requirement": {
                            "requirement_type": "prior lines of therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients with cutaneous melanoma",
                        "criterion": "cutaneous melanoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "may be naïve to all prior therapy for advanced or metastatic disease",
                                "criterion": "prior therapy for advanced or metastatic disease",
                                "requirement": {
                                    "requirement_type": "naivety",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "For BRAF wild type melanoma, patients should have received no more than 2 prior lines of therapy",
                                "criterion": "BRAF wild type melanoma",
                                "requirement": {
                                    "requirement_type": "prior lines of therapy",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "lines"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "For BRAF V600 mutant disease, patients should have received no more than 3 prior lines of therapy",
                                "criterion": "BRAF V600 mutant melanoma",
                                "requirement": {
                                    "requirement_type": "prior lines of therapy",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "lines"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Combination Dose Escalation:",
                "criterions": [
                    {
                        "exact_snippets": "Combination Dose Escalation",
                        "criterion": "combination dose escalation",
                        "requirement": {
                            "requirement_type": "participation",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Combination Dose Escalation",
                        "criterion": "combination dose escalation",
                        "requirement": {
                            "requirement_type": "participation",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Has at least 1 measurable lesion per RECIST 1.1(lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions);",
                "criterions": [
                    {
                        "exact_snippets": "at least 1 measurable lesion per RECIST 1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least 1 measurable lesion per RECIST 1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "measurability_standard",
                            "expected_value": "RECIST 1.1"
                        }
                    },
                    {
                        "exact_snippets": "lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions",
                        "criterion": "lesion in previously irradiated area",
                        "requirement": {
                            "requirement_type": "measurability_condition",
                            "expected_value": "progression demonstrated"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "at least 1 measurable lesion per RECIST 1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least 1 measurable lesion per RECIST 1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "measurability_standard",
                            "expected_value": "RECIST 1.1"
                        }
                    },
                    {
                        "exact_snippets": "lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions",
                        "criterion": "lesion in previously irradiated area",
                        "requirement": {
                            "requirement_type": "measurability_condition",
                            "expected_value": "progression demonstrated"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Arm D: Patients with RCC who have received no more than 3 prior lines of therapy",
                "criterions": [
                    {
                        "exact_snippets": "Arm D: Patients with RCC",
                        "criterion": "renal cell carcinoma (RCC)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": "renal cell carcinoma"
                        }
                    },
                    {
                        "exact_snippets": "no more than 3 prior lines of therapy",
                        "criterion": "number of prior lines of therapy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines of therapy"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Arm D: Patients with RCC",
                        "criterion": "renal cell carcinoma (RCC)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": "renal cell carcinoma"
                        }
                    },
                    {
                        "exact_snippets": "no more than 3 prior lines of therapy",
                        "criterion": "number of prior lines of therapy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines of therapy"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Additional criteria may apply",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "Combination Dose Expansion:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "Each patient must meet all the following criteria to participate in the study:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "18. Pregnant or lactating;",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "lactating",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Diagnosis of immunodeficiency, is on immunosuppressive therapy, or is receiving chronic systemic or enteric steroid therapy",
                "criterions": [
                    {
                        "exact_snippets": "Diagnosis of immunodeficiency",
                        "criterion": "immunodeficiency",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "is on immunosuppressive therapy",
                        "criterion": "immunosuppressive therapy",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "is receiving chronic systemic or enteric steroid therapy",
                        "criterion": "chronic systemic or enteric steroid therapy",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Diagnosis of immunodeficiency",
                        "criterion": "immunodeficiency",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "is on immunosuppressive therapy",
                        "criterion": "immunosuppressive therapy",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "is receiving chronic systemic or enteric steroid therapy",
                        "criterion": "chronic systemic or enteric steroid therapy",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Have received prior IL-2-directed therapy;",
                "criterions": [
                    {
                        "exact_snippets": "Have received prior IL-2-directed therapy",
                        "criterion": "prior IL-2-directed therapy",
                        "requirement": {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Have received prior IL-2-directed therapy",
                    "criterion": "prior IL-2-directed therapy",
                    "requirement": {
                        "requirement_type": "history of therapy",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "20. Additional criteria may apply.",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "17. Active infection as determined by hepatitis C virus (HCV) antibody or HCV RNA by qPCR testing;",
                "criterions": [
                    {
                        "exact_snippets": "Active infection as determined by hepatitis C virus (HCV) antibody or HCV RNA by qPCR testing",
                        "criterion": "hepatitis C virus (HCV) infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Active infection as determined by hepatitis C virus (HCV) antibody or HCV RNA by qPCR testing",
                        "criterion": "hepatitis C virus (HCV) infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease;",
                "criterions": [
                    {
                        "exact_snippets": "HIV-infected participants",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of Kaposi sarcoma",
                        "criterion": "Kaposi sarcoma",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of ... Multicentric Castleman Disease",
                        "criterion": "Multicentric Castleman Disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "HIV-infected participants",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "history of Kaposi sarcoma",
                                "criterion": "Kaposi sarcoma",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "history of ... Multicentric Castleman Disease",
                                "criterion": "Multicentric Castleman Disease",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Investigational agent or anticancer therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug;",
                "criterions": [
                    {
                        "exact_snippets": "Investigational agent or anticancer therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug",
                        "criterion": "prior investigational agent or anticancer therapy",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Investigational agent or anticancer therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug",
                    "criterion": "prior investigational agent or anticancer therapy",
                    "requirement": {
                        "requirement_type": "time since last administration",
                        "expected_value": {
                            "comparisons": [
                                {
                                    "operator": ">=",
                                    "value": 5,
                                    "unit": "half-lives"
                                },
                                {
                                    "operator": ">=",
                                    "value": 4,
                                    "unit": "weeks"
                                }
                            ]
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "19. History of hypersensitivity to any of the study drug components;",
                "criterions": [
                    {
                        "exact_snippets": "History of hypersensitivity to any of the study drug components",
                        "criterion": "hypersensitivity to study drug components",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "History of hypersensitivity to any of the study drug components",
                    "criterion": "hypersensitivity to study drug components",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "16. Active infection as determined by hepatitis B surface antigen and hepatitis B core antibody, or hepatitis B virus DNA by quantitative polymerase chain reaction (qPCR) testing;",
                "criterions": [
                    {
                        "exact_snippets": "Active infection as determined by hepatitis B surface antigen",
                        "criterion": "hepatitis B surface antigen",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active infection as determined by ... hepatitis B core antibody",
                        "criterion": "hepatitis B core antibody",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active infection as determined by ... hepatitis B virus DNA by quantitative polymerase chain reaction (qPCR) testing",
                        "criterion": "hepatitis B virus DNA (by qPCR)",
                        "requirement": {
                            "requirement_type": "detectable DNA",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Active infection as determined by hepatitis B surface antigen",
                        "criterion": "hepatitis B surface antigen",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active infection as determined by ... hepatitis B core antibody",
                        "criterion": "hepatitis B core antibody",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active infection as determined by ... hepatitis B virus DNA by quantitative polymerase chain reaction (qPCR) testing",
                        "criterion": "hepatitis B virus DNA (by qPCR)",
                        "requirement": {
                            "requirement_type": "detectable DNA",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Have known symptomatic brain metastases requiring steroids;",
                "criterions": [
                    {
                        "exact_snippets": "known symptomatic brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known symptomatic brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "requiring steroids",
                        "criterion": "steroid requirement for brain metastases",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "known symptomatic brain metastases",
                                "criterion": "brain metastases",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "known symptomatic brain metastases",
                                "criterion": "brain metastases",
                                "requirement": {
                                    "requirement_type": "symptomatic",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "requiring steroids",
                        "criterion": "steroid requirement for brain metastases",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Have an active autoimmune disease that required systemic treatment in the past 2 years;",
                "criterions": [
                    {
                        "exact_snippets": "active autoimmune disease that required systemic treatment in the past 2 years",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active autoimmune disease that required systemic treatment in the past 2 years",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic treatment"
                        }
                    },
                    {
                        "exact_snippets": "active autoimmune disease that required systemic treatment in the past 2 years",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "active autoimmune disease that required systemic treatment in the past 2 years",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active autoimmune disease that required systemic treatment in the past 2 years",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic treatment"
                        }
                    },
                    {
                        "exact_snippets": "active autoimmune disease that required systemic treatment in the past 2 years",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Has received prior radiotherapy within 2 weeks of start of study treatment. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease;",
                "criterions": [
                    {
                        "exact_snippets": "Has received prior radiotherapy within 2 weeks of start of study treatment",
                        "criterion": "prior radiotherapy",
                        "requirement": {
                            "requirement_type": "time since last radiotherapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease",
                        "criterion": "palliative radiation to non-CNS disease",
                        "requirement": {
                            "requirement_type": "duration of radiotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease",
                        "criterion": "palliative radiation to non-CNS disease",
                        "requirement": {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "not_criteria": {
                                "exact_snippets": "Has received prior radiotherapy within 2 weeks of start of study treatment",
                                "criterion": "prior radiotherapy",
                                "requirement": {
                                    "requirement_type": "time since last radiotherapy",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease",
                                "criterion": "palliative radiation to non-CNS disease",
                                "requirement": {
                                    "requirement_type": "duration of radiotherapy",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "not_criteria": {
                                        "exact_snippets": "A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease",
                                        "criterion": "palliative radiation to non-CNS disease",
                                        "requirement": {
                                            "requirement_type": "washout period",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 1,
                                                "unit": "week"
                                            }
                                        }
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Active, uncontrolled systemic bacterial, viral, or fungal infection;",
                "criterions": [
                    {
                        "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                        "criterion": "systemic bacterial infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                        "criterion": "systemic bacterial infection",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                        "criterion": "systemic viral infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                        "criterion": "systemic viral infection",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                        "criterion": "systemic fungal infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                        "criterion": "systemic fungal infection",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                                "criterion": "systemic bacterial infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                                "criterion": "systemic bacterial infection",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": "uncontrolled"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                                "criterion": "systemic viral infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                                "criterion": "systemic viral infection",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": "uncontrolled"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                                "criterion": "systemic fungal infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Active, uncontrolled systemic bacterial, viral, or fungal infection",
                                "criterion": "systemic fungal infection",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": "uncontrolled"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Have significant cardiovascular disease;",
                "criterions": [
                    {
                        "exact_snippets": "Have significant cardiovascular disease",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "Have significant cardiovascular disease",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Have significant cardiovascular disease",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Have significant cardiovascular disease",
                        "criterion": "cardiovascular disease",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "6. Agrees to undergo a pre-treatment and on-treatment biopsy of a primary or metastatic solid tumor lesion;",
                "criterions": [
                    {
                        "exact_snippets": "Agrees to undergo a pre-treatment and on-treatment biopsy of a primary or metastatic solid tumor lesion",
                        "criterion": "biopsy of a primary or metastatic solid tumor lesion",
                        "requirement": {
                            "requirement_type": "agreement to undergo procedure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Agrees to undergo a pre-treatment and on-treatment biopsy of a primary or metastatic solid tumor lesion",
                        "criterion": "biopsy of a primary or metastatic solid tumor lesion",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": [
                                "pre-treatment",
                                "on-treatment"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "1. Has histological or cytological documentation of a solid tumor indication for which a CPI (e.g. anti-PD-(L)1 is indicated for all parts of the clinical study;",
                "criterions": [
                    {
                        "exact_snippets": "Has histological or cytological documentation of a solid tumor indication",
                        "criterion": "solid tumor",
                        "requirement": {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "for which a CPI (e.g. anti-PD-(L)1 is indicated for all parts of the clinical study",
                        "criterion": "CPI (e.g. anti-PD-(L)1) indication",
                        "requirement": {
                            "requirement_type": "treatment_indication",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Arm A: Patients with relapsed advanced or metastatic RCC who have received no more than 4 prior lines of therapy in the advanced or metastatic setting",
                "criterions": [
                    {
                        "exact_snippets": "relapsed advanced or metastatic RCC",
                        "criterion": "renal cell carcinoma (RCC)",
                        "requirement": {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "advanced",
                                "metastatic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "no more than 4 prior lines of therapy in the advanced or metastatic setting",
                        "criterion": "prior lines of therapy in the advanced or metastatic setting",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "8. Willingness of men and women of reproductive potential to observe highly effective birth control for the duration of treatment and for 4 months following the last dose of study drug;",
                "criterions": [
                    {
                        "exact_snippets": "Willingness of men and women of reproductive potential to observe highly effective birth control for the duration of treatment and for 4 months following the last dose of study drug",
                        "criterion": "use of highly effective birth control",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Willingness of men and women of reproductive potential to observe highly effective birth control for the duration of treatment and for 4 months following the last dose of study drug",
                        "criterion": "use of highly effective birth control",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": [
                                "for the duration of treatment",
                                "for 4 months following the last dose of study drug"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Arm C: Patients with relapsed advanced or metastatic cSCC who have received no more than 1 prior line of therapy",
                "criterions": [
                    {
                        "exact_snippets": "relapsed advanced or metastatic cSCC",
                        "criterion": "cutaneous squamous cell carcinoma (cSCC)",
                        "requirement": {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "advanced",
                                "metastatic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "no more than 1 prior line of therapy",
                        "criterion": "prior lines of therapy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "lines of therapy"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "Patients with relapsed/refractory locally advanced or metastatic solid tumors for which immunotherapy is approved, who have progressed on or are intolerant to standard therapy, including CPIs, or for whom no standard therapy with proven benefit exists.",
                "criterions": [
                    {
                        "exact_snippets": "relapsed/refractory locally advanced or metastatic solid tumors",
                        "criterion": "solid tumors",
                        "requirement": {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "relapsed/refractory locally advanced or metastatic solid tumors",
                        "criterion": "solid tumors",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "for which immunotherapy is approved",
                        "criterion": "immunotherapy approval for tumor type",
                        "requirement": {
                            "requirement_type": "approval status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "who have progressed on or are intolerant to standard therapy, including CPIs",
                        "criterion": "response to standard therapy (including CPIs)",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "who have progressed on or are intolerant to standard therapy, including CPIs",
                        "criterion": "response to standard therapy (including CPIs)",
                        "requirement": {
                            "requirement_type": "intolerance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for whom no standard therapy with proven benefit exists",
                        "criterion": "availability of standard therapy with proven benefit",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Arm B: Patients with relapsed advanced or metastatic cutaneous malignant melanoma who have received no more than 2 prior lines of therapy for BRAF V600 wild type and no more than 3 prior lines of therapy for BRAF V600 mutant melanoma.",
                "criterions": [
                    {
                        "exact_snippets": "relapsed advanced or metastatic cutaneous malignant melanoma",
                        "criterion": "cutaneous malignant melanoma",
                        "requirement": {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "advanced",
                                "metastatic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "no more than 2 prior lines of therapy for BRAF V600 wild type",
                        "criterion": "prior lines of therapy for BRAF V600 wild type melanoma",
                        "requirement": {
                            "requirement_type": "number of prior lines of therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no more than 3 prior lines of therapy for BRAF V600 mutant melanoma",
                        "criterion": "prior lines of therapy for BRAF V600 mutant melanoma",
                        "requirement": {
                            "requirement_type": "number of prior lines of therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "Patients with relapsed/refractory locally advanced or metastatic solid tumors for which immunotherapy is approved, who have progressed on or are intolerant to standard therapy or for whom no standard therapy with proven benefit exists.",
                "criterions": [
                    {
                        "exact_snippets": "relapsed/refractory locally advanced or metastatic solid tumors",
                        "criterion": "solid tumors",
                        "requirement": {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "relapsed/refractory locally advanced or metastatic solid tumors",
                        "criterion": "solid tumors",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "solid tumors for which immunotherapy is approved",
                        "criterion": "solid tumors",
                        "requirement": {
                            "requirement_type": "immunotherapy approval",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "who have progressed on or are intolerant to standard therapy",
                        "criterion": "standard therapy",
                        "requirement": {
                            "requirement_type": "progression on therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "who have progressed on or are intolerant to standard therapy",
                        "criterion": "standard therapy",
                        "requirement": {
                            "requirement_type": "intolerance to therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "for whom no standard therapy with proven benefit exists",
                        "criterion": "standard therapy with proven benefit",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "9. Major surgery (excluding placement of vascular access) within 2 weeks prior to the first dose of study drug;",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery (excluding placement of vascular access) within 2 weeks prior to the first dose of study drug",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Major surgery (excluding placement of vascular access) within 2 weeks prior to the first dose of study drug",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "2. Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease;",
                "criterions": [
                    {
                        "exact_snippets": "history of (non-infectious) pneumonitis / interstitial lung disease that required steroids",
                        "criterion": "(non-infectious) pneumonitis / interstitial lung disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of (non-infectious) pneumonitis / interstitial lung disease that required steroids",
                        "criterion": "(non-infectious) pneumonitis / interstitial lung disease",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    },
                    {
                        "exact_snippets": "current pneumonitis / interstitial lung disease",
                        "criterion": "pneumonitis / interstitial lung disease",
                        "requirement": {
                            "requirement_type": "current presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Have had an allogeneic tissue/solid organ transplant;",
                "criterions": [
                    {
                        "exact_snippets": "Have had an allogeneic tissue/solid organ transplant",
                        "criterion": "allogeneic tissue/solid organ transplant",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "13. Received a live or live-attenuated vaccine within 30 days of the first dose of study drug; Note: Administration of killed vaccines or other formats are allowed.",
                "criterions": [
                    {
                        "exact_snippets": "Received a live or live-attenuated vaccine within 30 days of the first dose of study drug",
                        "criterion": "live or live-attenuated vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Administration of killed vaccines or other formats are allowed",
                        "criterion": "killed or other format vaccine administration",
                        "requirement": {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Received a live or live-attenuated vaccine within 30 days of the first dose of study drug",
                        "criterion": "live or live-attenuated vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Have a history of another active malignancy (a second cancer) within the previous 2 years except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, presents a low risk of recurrence. These exceptions include, but are not limited to, basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast;",
                "criterions": [
                    {
                        "exact_snippets": "Have a history of another active malignancy (a second cancer) within the previous 2 years",
                        "criterion": "history of another active malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Have a history of another active malignancy (a second cancer) within the previous 2 years",
                        "criterion": "history of another active malignancy",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, presents a low risk of recurrence. These exceptions include, but are not limited to, basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast;",
                        "criterion": "history of certain localized cancers",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "basal cell skin cancer",
                                "squamous cell skin cancer",
                                "superficial bladder cancer",
                                "carcinoma in situ of the prostate",
                                "carcinoma in situ of the cervix",
                                "carcinoma in situ of the breast"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, presents a low risk of recurrence. These exceptions include, but are not limited to, basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast;",
                        "criterion": "history of certain localized cancers",
                        "requirement": {
                            "requirement_type": "relation to current cancer",
                            "expected_value": "not related"
                        }
                    },
                    {
                        "exact_snippets": "except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, presents a low risk of recurrence. These exceptions include, but are not limited to, basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast;",
                        "criterion": "history of certain localized cancers",
                        "requirement": {
                            "requirement_type": "cure status",
                            "expected_value": "considered cured"
                        }
                    },
                    {
                        "exact_snippets": "except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, presents a low risk of recurrence. These exceptions include, but are not limited to, basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast;",
                        "criterion": "history of certain localized cancers",
                        "requirement": {
                            "requirement_type": "risk of recurrence",
                            "expected_value": "low (in the opinion of the Investigator)"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "12. Any unresolved toxicities from prior therapy greater than NCI CTCAE version 5.0 Grade 1 at the time of starting study drug with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy;",
                "criterions": [
                    {
                        "exact_snippets": "Any unresolved toxicities from prior therapy greater than NCI CTCAE version 5.0 Grade 1 at the time of starting study drug",
                        "criterion": "unresolved toxicities from prior therapy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "NCI CTCAE v5.0 Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "with the exception of alopecia",
                        "criterion": "alopecia",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Grade 2 prior platinum-therapy related neuropathy",
                        "criterion": "prior platinum-therapy related neuropathy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "NCI CTCAE v5.0 Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Grade 2 prior platinum-therapy related neuropathy",
                        "criterion": "prior platinum-therapy related neuropathy",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any unresolved toxicities from prior therapy greater than NCI CTCAE version 5.0 Grade 1 at the time of starting study drug",
                                "criterion": "unresolved toxicities from prior therapy",
                                "requirement": {
                                    "requirement_type": "severity",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "NCI CTCAE v5.0 Grade"
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "or_criteria": [
                                        {
                                            "exact_snippets": "with the exception of alopecia",
                                            "criterion": "alopecia",
                                            "requirement": {
                                                "requirement_type": "exception",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "and_criteria": [
                                                {
                                                    "exact_snippets": "Grade 2 prior platinum-therapy related neuropathy",
                                                    "criterion": "prior platinum-therapy related neuropathy",
                                                    "requirement": {
                                                        "requirement_type": "severity",
                                                        "expected_value": {
                                                            "operator": "=",
                                                            "value": 2,
                                                            "unit": "NCI CTCAE v5.0 Grade"
                                                        }
                                                    }
                                                },
                                                {
                                                    "exact_snippets": "Grade 2 prior platinum-therapy related neuropathy",
                                                    "criterion": "prior platinum-therapy related neuropathy",
                                                    "requirement": {
                                                        "requirement_type": "exception",
                                                        "expected_value": true
                                                    }
                                                }
                                            ]
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}